Adagio Medical completes enrollment in FULCRUM-VT trial

Adagio Medical (ADGM) announced the completion of enrollment of the FULCRUM-VT FDA investigational device exemption study evaluating the company’s vCLAS Cryoablation System for ablation of monomorphic ventricular tachycardia. The vCLAS System, which has been granted breakthrough device designation by the FDA, is built on the company’s proprietary ultra-low temperature cryoablation technology platform.